Contract Win
IXICO PLC
("IXICO" or the "Company")
US Client Clinical Trial Contract Win
10 December 2024 - London, UK. IXICO plc (AIM: IXI, "IXICO" or "the Company") a global leader in neuroscience imaging, using its AI-driven platform to help advance therapy research in neurological disorders, today announces that it has signed a contract with a new US headquartered client to provide imaging services for a Phase 2 Huntington's Disease clinical trial. The contract value, to be delivered over approximately 2.5 years, is worth over £0.5 million to IXICO.
Huntington's Disease is a rare, hereditary neurodegenerative disorder that leads to the progressive breakdown of nerve cells in the brain, affecting motor skills, cognitive function, mood, and emotional well-being.
The contract award reinforces IXICO's sustained positive commercial momentum, as highlighted in the Company's FY24 Final Results, and aligns with its strategic pillars of 'Innovate, Lead, Scale' to drive expansion and growth. Throughout 2024, IXICO has also secured additional clinical trial contracts across key therapeutic areas, including Huntington's Disease, Parkinsonian Disorders, and Alzheimer's Disease.
Bram Goorden, CEO of IXICO, commented: "We are delighted to announce our involvement in this Phase 2 clinical trial, which aims to address the urgent need for effective treatments for Huntington's disease. This contract further demonstrates IXICO's expertise in supporting neurodegenerative disease trials, reinforcing our role as a trusted partner for sponsors. Through this work we are proud to continue our support of the Huntington's Disease community, in collaboration with our sponsor, working towards a breakthrough in this challenging field."
Ends
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the UK version of the EU Market Abuse Regulation 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended and supplemented from time to time. Upon the publication of this announcement, this inside information is now considered to be in the public domain.
Further information:
IXICO plc | +44 (0) 20 3763 7499 | ||
Bram Goorden, Chief Executive Officer Grant Nash, Chief Financial Officer |
| ||
| |||
Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker) | +44 (0) 20 7220 0500 | ||
Giles Balleny / Dan Hodkinson (Corporate Finance) Nigel Birks/Harriet Ward (Corporate Broking) Michael F Johnson / Tamar Cranford Smith (Sales) | |||
About IXICO www.IXICO.com
IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.
IXICO has developed and deployed breakthrough data analytics, at scale, through its remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.